Guarav Dutta, MD
Pulmonary Disease · Lagrange, GANPI 1891026126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 44.8% of the total. Reporting peaked in 2019 at $134 and has fallen 56.1% since, to $59 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 21 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$155
- Novartis$72
- Viatris Specialty LLC$59
- Sunovion Pharmaceuticals Inc.$20
- Johnson & Johnson$15
- AstraZeneca$15
- plus $10 from 1 others
What the payments were for
- Food & beverage$346100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 11 | $155 |
| Novartis | 5 | $72 |
| Viatris Specialty LLC | 1 | $59 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $10 |
How this compares
$346 in reported general payments places this provider in the 15th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 13 | $73 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lagrange
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.